382 Shares in IDEXX Laboratories, Inc. (NASDAQ:IDXX) Bought by OneAscent Wealth Management LLC

OneAscent Wealth Management LLC acquired a new position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 382 shares of the company’s stock, valued at approximately $206,000.

Several other institutional investors also recently modified their holdings of the business. Franklin Resources Inc. grew its stake in shares of IDEXX Laboratories by 2.1% in the fourth quarter. Franklin Resources Inc. now owns 1,405,824 shares of the company’s stock worth $780,303,000 after purchasing an additional 28,475 shares during the last quarter. Morgan Stanley grew its stake in shares of IDEXX Laboratories by 4.7% in the third quarter. Morgan Stanley now owns 1,064,514 shares of the company’s stock worth $465,482,000 after purchasing an additional 48,095 shares during the last quarter. Capital World Investors boosted its position in IDEXX Laboratories by 1.1% during the fourth quarter. Capital World Investors now owns 1,022,678 shares of the company’s stock valued at $567,648,000 after acquiring an additional 11,351 shares during the last quarter. Norges Bank bought a new stake in IDEXX Laboratories during the fourth quarter valued at $512,190,000. Finally, JPMorgan Chase & Co. boosted its position in IDEXX Laboratories by 8.9% during the third quarter. JPMorgan Chase & Co. now owns 801,274 shares of the company’s stock valued at $350,373,000 after acquiring an additional 65,760 shares during the last quarter. Institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Trading Down 1.4 %

IDXX opened at $487.20 on Friday. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.57 and a quick ratio of 1.16. IDEXX Laboratories, Inc. has a fifty-two week low of $372.50 and a fifty-two week high of $583.39. The firm has a market capitalization of $40.24 billion, a PE ratio of 47.16, a P/E/G ratio of 4.03 and a beta of 1.33. The company’s 50-day moving average is $501.58 and its 200 day moving average is $526.81.

IDEXX Laboratories (NASDAQ:IDXX) last posted its earnings results on Wednesday, May 1st. The company reported $2.81 earnings per share for the quarter, topping analysts’ consensus estimates of $2.68 by $0.13. IDEXX Laboratories had a net margin of 23.26% and a return on equity of 63.66%. The company had revenue of $964.10 million for the quarter, compared to analyst estimates of $965.43 million. As a group, research analysts predict that IDEXX Laboratories, Inc. will post 11.03 earnings per share for the current fiscal year.

Analysts Set New Price Targets

IDXX has been the topic of a number of research analyst reports. Barclays cut their price target on shares of IDEXX Laboratories from $655.00 to $570.00 and set an “overweight” rating on the stock in a research report on Thursday, May 2nd. StockNews.com raised shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a research report on Friday, June 14th. Morgan Stanley cut their price target on shares of IDEXX Laboratories from $620.00 to $596.00 and set an “overweight” rating on the stock in a research report on Tuesday, May 14th. Stifel Nicolaus cut their price target on shares of IDEXX Laboratories from $520.00 to $510.00 and set a “hold” rating on the stock in a research report on Monday, June 24th. Finally, William Blair reiterated an “outperform” rating on shares of IDEXX Laboratories in a report on Tuesday, April 9th. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $586.63.

Insider Buying and Selling at IDEXX Laboratories

In other IDEXX Laboratories news, Director Bruce L. Claflin sold 200 shares of the stock in a transaction dated Friday, May 17th. The shares were sold at an average price of $540.80, for a total value of $108,160.00. Following the completion of the sale, the director now owns 161 shares in the company, valued at approximately $87,068.80. The transaction was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 2.11% of the company’s stock.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.